GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sorrento Therapeutics Inc (OTCPK:SRNE) » Definitions » Cyclically Adjusted Price-to-FCF

Sorrento Therapeutics (Sorrento Therapeutics) Cyclically Adjusted Price-to-FCF : (As of Apr. 27, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Sorrento Therapeutics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sorrento Therapeutics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Sorrento Therapeutics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sorrento Therapeutics Cyclically Adjusted Price-to-FCF Chart

Sorrento Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sorrento Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sorrento Therapeutics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Sorrento Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sorrento Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sorrento Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Sorrento Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Sorrento Therapeutics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Sorrento Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2023 is calculated as:

For example, Sorrento Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=-0.101/128.7287*128.7287
=-0.101

Current CPI (Jun. 2023) = 128.7287.

Sorrento Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201309 -0.256 98.790 -0.334
201312 -0.359 98.326 -0.470
201403 -0.400 99.695 -0.516
201406 -0.256 100.560 -0.328
201409 -0.204 100.428 -0.261
201412 -0.263 99.070 -0.342
201503 -0.254 99.621 -0.328
201506 0.031 100.684 0.040
201509 -0.531 100.392 -0.681
201512 -0.474 99.792 -0.611
201603 -0.547 100.470 -0.701
201606 -0.297 101.688 -0.376
201609 -0.355 101.861 -0.449
201612 -0.335 101.863 -0.423
201703 -0.512 102.862 -0.641
201706 -0.318 103.349 -0.396
201709 -0.198 104.136 -0.245
201712 -0.559 104.011 -0.692
201803 -0.287 105.290 -0.351
201806 -0.243 106.317 -0.294
201809 -0.202 106.507 -0.244
201812 -0.414 105.998 -0.503
201903 -0.405 107.251 -0.486
201906 -0.371 108.070 -0.442
201909 -0.341 108.329 -0.405
201912 -0.229 108.420 -0.272
202003 -0.211 108.902 -0.249
202006 -0.177 108.767 -0.209
202009 -0.263 109.815 -0.308
202012 -0.079 109.897 -0.093
202103 -0.168 111.754 -0.194
202106 -0.283 114.631 -0.318
202109 -0.282 115.734 -0.314
202112 -0.241 117.630 -0.264
202203 -0.255 121.301 -0.271
202206 -0.208 125.017 -0.214
202209 -0.144 125.227 -0.148
202212 -0.150 125.222 -0.154
202303 -0.091 127.348 -0.092
202306 -0.101 128.729 -0.101

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sorrento Therapeutics  (OTCPK:SRNE) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Sorrento Therapeutics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Sorrento Therapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Sorrento Therapeutics (Sorrento Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
4955 Directors Place, San Diego, CA, USA, 92121
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.
Executives
Henry Ji director, officer: See Remarks 5370 RUETTE DE MER, SAN DIEGO CA 92130
Tammy Reilly director C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Kim Janda director 6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121
Elizabeth Czerepak director 201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Dorman Followwill director C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Najjam Asghar officer: Chief Financial Officer C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Robin L Smith director C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
Edgar Lee director C/O OAKTREE CAPITAL MANAGEMENT, L.P., 333 SOUTH GRAND AVE, 28TH FLOOR, LOS ANGELES CA 90071
Jerome B Zeldis officer: See Remarks 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Jaisim Shah director C/O PROTINE DESIGN LAB, 37481 MARSTEN DR, NEWARK CA 94560
Yue Alexander Wu director C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121
David Lemus director C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Abg Management Ltd 10 percent owner UNIT 3002-04,30TH FLOOR,GLOUCESTER TOWER, THE LANDMARK,15 QUEEN'S ROAD CENTRAL, HONG KONG K3 000000
Jiong Shao officer: Chief Financial Officer SUITE 1003-1004, 10/F, ICBC TOWER, THREE GARDEN ROAD, CENTRAL, HONG KONG F4 000000
George K Ng officer: See Remarks C/O SORRENTO THERAPEUTICS, INC., 6042 CORNERSTONE COURT WEST, SUITE B, SAN DIEGO CA 92121

Sorrento Therapeutics (Sorrento Therapeutics) Headlines

From GuruFocus